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Although activated murine NK cells can use the
granule exocytosis pathway to kill target cells
immediately upon recognition, resting murine
NK cells are minimally cytotoxic for unknown
reasons. Here, we showed that resting NK cells
contained abundant granzyme A, but little gran-
zyme B or perforin; in contrast, the mRNAs
for all three genes were abundant. Cytokine-
induced in vitro activation of NK cells resulted
in potent cytotoxicity associated with a dra-
matic increase in granzyme B and perforin,
but only minimal changes in mRNA abundance
for these genes. The same pattern of regulation
was found in vivo with murine cytomegalovirus
infection as a physiologic model of NK cell acti-
vation. These data suggest that resting murine
NK cells are minimally cytotoxic because of
a block in perforin and granzymeBmRNA trans-
lation that is released by NK cell activation.
INTRODUCTION
Natural-killer (NK) cells are innate immune lymphocytes
that are important for early host defense against infectious
pathogens and tumors through two primary mechanisms:
contact-dependent cytotoxicity and cytokine production
(Biron and Brossay, 2001; Yokoyama et al., 2004). NK
cells were first identified by their ability to kill tumor target
cells without prior sensitization via a specific antigen re-
ceptor, a trait that distinguishes NK cells from cytotoxic
T cells (Herberman et al., 1975; Kiessling et al., 1975).
NK cell responses to potential target cells are determined
by the integration of multiple triggering signals from fami-
lies of cell-surface-activating and -inhibitory NK receptors
(Lanier, 2005; Yokoyama and Kim, 2006). Although NK
cells can induce target-cell death through several mecha-
nisms, the granule-exocytosis pathway is the primary one
used by NK cells to kill tumor and virus-infected cells798 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.(Grossman et al., 2003; Henkart, 1985; Lieberman, 2003;
Russell and Ley, 2002). Therefore, to kill a target cell, an
NK cell must be triggered by engagement of NK cell re-
ceptors, and it must contain functional cytotoxic granules.
Cytotoxic lymphocyte granules contain many compo-
nent proteins, including perforin (Prf1) and granzymes
(Gzms); Prf1 facilitates the entry and/or trafficking of
Gzms into target cells, where these proteases induce cell
death (Russell and Ley, 2002). Of the Gzms, A and B are
the best characterized, and they have been shown to initi-
ate target-cell death by cleaving nonoverlapping sets of
substrates (Lieberman, 2003; Russell and Ley, 2002).
Much of our understanding of murine NK cell Prf1 and
Gzm expression is derived from experiments with human
NK cells, cell lines, cytotoxic T cells, and lymphokine-acti-
vated-killer (LAK) cells (Babichuk et al., 1996; Ebnet et al.,
1995b; Garcia-Sanz et al., 1990; Grossman et al., 2003;
Russell and Ley, 2002; Smyth et al., 1995). Studies utilizing
CD8+ cytotoxic T lymphocytes (CTL) have shown that the
expression of Prf1 and Gzmb are controlled primarily at
the level of transcription in effector T cells—a finding that
has been generalized to all cytotoxic lymphocytes (Babi-
chuk and Bleackley, 1997; Babichuk et al., 1996; Garcia-
Sanz et al., 1990; Hanson and Ley, 1990; Heusel et al.,
1994; Shresta et al., 1999). Studies that used murine LAK
cells (generated by long-term culture of splenocytes in
high doses of IL-2) as ‘‘NK cell surrogates’’ have shown
that these cells contain abundant mRNA and protein for
Gzma, Gzmb, and Prf1 (Pham et al., 1996; Revell et al., 2005;
Shresta et al., 1995, 1997, 1999). The current view of mu-
rine NK cells as being ‘‘armed’’ with Prf1 and Gzm protein
was derived from these prior studies; however, it is not
clear that humanNK cells, LAK cells, cell lines, or T cells re-
flect the true biology of murine NK cells. Paradoxically, it
has long been recognized that resting murine NK cells are
minimally cytotoxic against tumor targets in vitro, and it is
unclear why activation is required to induce cytotoxicity.
Here we show that most resting murine NK cells contain
Gzma, but little or no Prf1 or Gzmb protein, yet they
express abundant mRNAs for all three genes. Whereas
resting NK cells are minimally cytotoxic against tumor
target cells in vitro, cytokine-induced in vitro activation
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Perforin and Granzyme A/B in Murine NK CellsFigure 1. Resting Murine NK Cells Express Abundant Gzma but Little Gzmb or Prf1 Protein
Resting splenocytes fromB6mice (A), freshly isolatedmononuclear cells from various B6mouse tissues (B), or resting splenocytes from the indicated
strains of mice (C) were gated on NK1.1+CD3 or DX5+CD3 NK cells and analyzed for expression of intracellular Gzma, Gzmb, or Prf1. Individual
flow-cytometry plots are shown and are representative of at least 30 (A), 5 (B), or 3 (C) independent experiments (see Results for summary statistics).
Numbers indicate the percentage of cells in each quadrant.of NK cells results in potent killing associated with a dra-
matic increase in Gzmb and Prf1 protein, with minimal
changes in mRNA abundance. Furthermore, the expres-
sion of Gzmb and Prf1 protein in NK cells is induced after
murine-cytomegalovirus (MCMV) infection in vivo, and
both Gzmb/ and Prf1/ B6 mice are more susceptible
to MCMV than are wild-type (WT) mice. These data sug-
gest that resting murine NK cells are minimally cytotoxic
because of a block in Prf1 and Gzmb mRNA translation
that is released by NK cell activation.RESULTS
Resting Murine NK Cells Contain Abundant Gzma
but Minimal Gzmb or Prf1 Protein
Although it is widely thought that all NK cells constitutively
express Prf1 and Gzms in cytotoxic granules, murine NK
cells are minimally cytotoxic against tumor targets in vitro
for unclear reasons. We therefore analyzed resting murine
NK cells for their Gzma, Gzmb, and Prf1 protein expres-
sion by using intracellular flow cytometry (Figure 1). ForImmunity 26, 798–811, June 2007 ª2007 Elsevier Inc. 799
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Perforin and Granzyme A/B in Murine NK CellsFigure 2. Cytokine-Activated Murine NK Cells Express Abundant Gzmb and Prf1 Protein
(A) Cytokine-activated NK cells express Gzmb and Prf1 protein by flow cytometry. Splenocytes were cultured with no cytokines (media) or the
following cytokines for 48 hr: rhIL-2 (1000 IU/mL), rmIL-12 (100 ng/mL), rmIL-15 (100 ng/mL), rmIL-18 (100 ng/mL), or rmIFN-a (100 U/mL), and
flow-cytometry plots of NK1.1+CD3 NK cell expression of Gzma, Gzmb, and Prf1 are shown. Results from an individual experiment are shown
and are representative of at least three independent experiments. Numbers indicate the percentage of cells in each quadrant.800 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.
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Perforin and Granzyme A/B in Murine NK Cellsall flow-cytometry experiments, bulk splenocytes were
first gated on NK1.1+CD3 or DX5+CD3 NK cells, and
the expression of Gzma, Gzmb, and Prf1 was examined
with monoclonal antibodies (mAbs) that have proven
specificity in the appropriate mutant mice (Figure S1 in
the Supplemental Data available online; Grossman et al.,
2004b). Surprisingly, the majority of resting splenic NK
cells from C57Bl/6 (B6) mice expressed abundant Gzma
(86.4% ± 2.1% positive, n = 22); however, there was little
or no expression of Gzmb (3.3% ± 4.6% positive, n = 22)
or Prf1 (1.9% ± 2.2% positive, n = 14) (Figures 1A, 1B,
and 2). NK cells in the blood, liver, and bone marrow
demonstrated a similar Gzma+GzmbPrf1 phenotype
(Figure 1B). Fewer bone-marrowNK1.1+CD3NKcells ex-
pressedGzma, compared to cells derived from the spleen,
liver, or blood (Figure 1B). A similar resting phenotype was
observed in 129/SvJ,BALB/c,CBA, andA/Jmouse strains
(Figure 1C). A/J mice had fewer Gzma+ NK cells at rest,
with a smaller amount of Gzmaper positive NK cell. Murine
CD8+ and CD4+ T cells in resting spleens do not express
Gzma, Gzmb, or Prf1, as expected (data not shown).
Prf1 andGzmprotein expression in restingmurineNKcells
differs from that of human peripheral blood CD56+CD3
NK cells, which constitutively express Gzmb and Prf1
protein (Figure S2; Bratke et al., 2005; Grossman et al.,
2004b). Thus,murineNKcells unexpectedly contain abun-
dant Gzma but minimal Gzmb or Prf1 protein.
Activated Murine NK Cells Express Gzmb and Prf1
Protein and Contain Azurophilic Granules
Cytokines are well-characterized stimulators of NK cell
cytotoxicity in vitro. We therefore examined the ability of
IL-2, IL-12, IL-15, IL-18, and IFN-a to alter Gzma, Gzmb,
and Prf1 protein expression in murine NK cells. Spleno-
cytes were cultured in the indicated cytokines for 48 hr,
and NK1.1+CD3 NK cells were analyzed (Figure 2A).
Whereas IL-2, IL-12, IL-18, and IFN-a all increased the
percentage of NK cells expressing Gzmb and Prf1 after
48 hr, IL-15 consistently induced the highest amount.
Stimulation of flow-sorted (R99% NK1.1+CD3) NK cells
with these cytokines for 48 hr revealed that IL-2 and IL-15
induced similar amounts of Gzmb and Prf1, whereas IL-
12, IL-18, and IFN-a induced less expression of these
proteins (Figure S3). We therefore performed an in-depth
analysis of Gzma, Gzmb, and Prf1 protein expression by
using IL-15 to activate NK cells (Figures 2B–2D). The per-
centage of Gzma+ NK cells did not change substantially
with 48 hr of IL-15 activation. IL-15 stimulated a time-
and dose-dependent increase in the percentage of cells
expressing Gzmb and Prf1 protein (Figures 2B–2D). Thepercentage of Gzmb+ NK cells increased after 6 hr and
continued to increase at 24 hr (86.4% ± 9.1%, p <
0.0001) and 48 hr (86% ± 11.8%, p < 0.0001). Prf1 protein
was increased in a small percentage of NK cells at 6–12 hr,
with further increases at 24 hr (30.4% ± 13.3%, p < 0.01)
and 48 hr (45.2% ± 19.6%, p < 0.001; Figures 2B and
2C). IL-15 increased Gzmb and Prf1 abundance at con-
centrations of 5 ng/mL; however, maximal induction was
observed withR50 ng/mL (Figure 2D). Increased NK cell
Gzmb and Prf1 was observed after IL-15 stimulation in
all strains tested (129/SvJ, BALB/c, CBA, and A/J;
Figure S4).
To extend these findings, we used flow sorting to isolate
highly purified NK cell populations (R99% NK1.1+CD3;
data not shown) from the spleens of B6 Rag1/ mice.
We compared purified NK cells and bulk WT B6 spleno-
cytes for Prf1 and Gzmb protein expression at rest, and
after stimulation with IL-15 for 24 hr or 48 hr, by using
immunoblot analysis (Figure 3A). These experiments
utilized an independent Prf1 mAb and a different
polyclonal Gzmb antibody, both of which have proven
specificities in their respective mutant mice (Revell et al.,
2005; Shresta et al., 1999). Purified resting NK cells con-
tained minimal Gzmb and Prf1 protein according to this
assay, with increased abundance after 24 and 48 hr of
stimulation with IL-15. Consistent with the immunoblot
data, the percentage of Prf1-containing cells (and the
Prf1 MFI) measured by flow cytometry increased only
modestly at 24 hr, with amore dramatic increase apparent
in both assays at 48 hr. No signal was detected for Gzmb
and Prf1 by immunoblot in resting bulk splenocytes, and
minimal signals were detected after 48 hr of IL-15 stimula-
tion. BecauseNK cells comprise only3%of total spleno-
cytes, the low signal intensities detected suggest that
these proteins are induced only in the NK population,
consistent with the flow-cytometry data.
Microscopic examination of flow-sorted resting NK
cells revealed small lymphocytes with little cytoplasm
and few cytoplasmic granules (Figure 3B). In contrast,
IL-15-activated NK cells were large and had open nuclear
chromatin, abundant cytoplasm, a prominent Golgi, and
abundant azurophilic (cytotoxic) granules. Thus, resting
murine NK cells require short-term activation (e.g., by IL-
15 or IL-2) to become ‘‘armed’’ withGzmb andPfr1 protein
and to develop large granular lymphocyte morphology.
Gzma, Gzmb, and Prf1 mRNA Change Minimally
with NK Cell Activation
We next examined the expression of Gzma, Gzmb, and
Prf1 mRNAs in flow-sorted (R99% NK1.1+CD3) resting(B and C) IL-15-treated NK cells express Gzmb and Prf1 protein in a time-dependent fashion. Splenocytes were stimulated with 100 ng/mL IL-15 for
0 (resting), 6, 12, 18, 24, or 48 hr, and NK1.1+CD3NK cells were analyzed for expression of intracellular Gzma, Gzmb, and Prf1. Representative flow-
cytometry plots from individual splenocyte cultures (B), and summary scatter plots of the percent positive NK1.1+CD3NK cells for Gzma, Gzmb, and
Prf1 from at least six independent experiments (C) are shown, with each data point representing an individual mouse. Horizontal bars represent mean
percent positive NK1.1+CD3 cells. *p < 0.01; **p < 0.001; ***p < 0.0001.
(D) IL-15-activated NK cells express Gzmb and Prf1 in a dose-dependent fashion. Splenocytes were stimulated with the indicated concentrations of
rmIL-15 for 48 hr, and NK1.1+CD3 NK cells were analyzed by flow cytometry for intracellular Gzma, Gzmb, and Prf1. Results shown are represen-
tative of at least three independent experiments.Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc. 801
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Perforin and Granzyme A/B in Murine NK CellsFigure 3. IL-15 Induces Gzmb and Prf1
Protein Expression and Granule Forma-
tion in Murine NK Cells
(A) Immunoblots of resting and activated NK
cells or bulk splenocytes for Prf1 (66 kDa)
and Gzmb (30 kDa). Protein lysates were
made from bulk splenocytes or flow-sorted
NK cells at rest (fresh) or after stimulation
with IL-15 for 24 hr or 48 hr. The murine NK
cell line 36.2 (which constitutively expresses
Prf1 and Gzmb) is shown as a positive control
(+ control), and actin is used as a loading con-
trol. NK, NK cells; SP, spleen; NS, nonspecific
band. Results shown are representative of two
independent experiments.
(B) IL-15 induces the formation of azurophilic
granules in purified murine NK cells. Light-
microscopic evaluation (10003) of flow-sorted
murine NK cells at rest or after 24 hr stimulation
with IL-15 (100 ng/mL). Note the large size,
open nuclear chromatin, prominent Golgi,
and abundant azurophilic granules in the IL-
15-stimulated NK cells, compared with resting
NK cells. Results shown are representative of
three independent experiments.and IL-15-activated murine NK cells by using Affymetrix
430v2.0 gene-expression microarrays (Figure 4). Gzma
was one of the most abundant mRNAs in resting NK cells,
and IL-15 stimulation did not markedly alter its mRNA
abundance (0.69-fold change). Both Gzmb and Prf1
mRNAs were abundantly expressed in resting NK cells;
whereas IL-15 modestly increased Gzmb mRNA
abundance (2.5-fold, p < 0.05) at 24 hr, Prf1 mRNA
expression was unchanged (0.78-fold change). Gzma,
Gzmb, and Prf1 all ranked (mean rank order from three
microarrays) in the top 500 expressed genes in resting
(Gzma, #3; Gzmb, #411; Prf1, #141) and IL-15-activated
(Gzma, #4; Gzmb, #30; Prf1, #182) NK cells (of the
45,037 probe sets represented on the array) (Figure 4C).
To confirm these findings, quantitative real-time RT-PCR
was performed via RNA from flow-sorted NK cells at rest
and after 24 hr IL-15 stimulation (Figure 4D). Consistent
with the microarray findings, Gzma and Prf1 mRNA
expression was not significantly different between resting
and IL-15-activated NK cells. Gzmb mRNA abundance
increased modestly after 24 hr of IL-15 stimulation (4.2-
fold, p < 0.05). Thus, resting murine NK cells are pre-
armed with abundant Gzmb and Prf1 mRNA, but minimal
Gzmb and Prf1 protein.
Cytokine Activation Arms Murine NK Cells
to Become Potent Cytotoxic Effectors
We next evaluated the cytotoxic potential of resting and
IL-15-activated splenocytes in a flow-based killing assay
(FloKA). Resting splenocytes were used as effectors
against the NK-sensitive target-cell lines RMAS and
YAC1, with minimal killing observed in a 4 hr FloKA (Fig-
ure 5A). At an effector:target (E:T) ratio of 20:1, resting802 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.splenocytes induced only 5.6% ± 2.8% (mean ± SD,
n = 7) 7-AAD+ RMAS target cells, and 7.3% ± 4.1% 7-
AAD+ YAC1 (n = 3) target cells. In contrast, IL-15-acti-
vated splenocytes used at an identical E:T ratio yielded
54.8% ± 11.1% 7-AAD+ RMAS (n = 14, p < 0.0001)
and 53.2% ± 13.6% 7-AAD+ YAC1 (n = 7, p < 0.001)
cells. The NK cell-insensitive EL4 cell line was minimally
killed by resting or IL-15-activated splenic NK cells, as
expected. We observed the same killing phenotype for
all strains of mice evaluated (Figure 5B). Identical B6
splenocyte effectors and RMAS targets were also com-
pared in parallel Cr51-release assays, which showed sim-
ilar results (Figures 5C and 5D). The percentages of
NK1.1+CD3 or DX5+CD3 NK cells changed only
slightly between fresh (2.6% ± 0.4%), 24 hr IL-15
(2.5% ± 0.3%), or 48 hr IL-15 (3.6% ± 0.6%) spleen cul-
tures, and thus had a minimal impact on the E:T ratios
used. Flow-sorted NK cells from Rag1/ mice demon-
strated minimal cytotoxicity against RMAS targets at
rest, which was dramatically increased after stimulation
with IL-15 (Figure S5).
Because NKG2D is also induced after IL-15 stimulation,
and could potentially mediate increased NK cytotoxicity,
we performed experiments comparing IL-15-activated
splenocytes preincubated with a blocking NKG2D (C7)
mAb or a hamster IgG control mAb (Ho et al., 2002). There
was no effect of NKG2D blockade on killing, suggesting
that activation of NKG2D did not contribute to increased
cytotoxicity in this setting (data not shown).
Thus, murine NK cells are minimally cytotoxic at rest
and require activation (e.g., by IL-15) to acquire the poten-
tial for potent cytotoxicity against NK-sensitive target cells
in vitro.
Immunity
Perforin and Granzyme A/B in Murine NK CellsFigure 4. Resting Murine NK Cells Express Abundant Gzma, Gzmb, and Prf1 mRNA, but Only Gzmb mRNA Increases with IL-15
Stimulation
(A and B) Gzma, Gzmb, and Prf1 mRNA expression detected on microarrays from resting and IL-15-activated NK cells.
(A) Flow-sorted NK cells were stimulated with 100 ng/mL of IL-15 for 0 hr (rest) or 24 hr, and total mRNA was isolated, labeled, and hybridized with
Affymetrix 430v2.0 expressionmicroarrays. Signal intensities of probe sets for Gzma, Gzmb, Prf1, and b-actin (control for [D]) from three independent
NK cell experiments are shown with the mean indicated by horizontal bar. *p < 0.05.
(B) Representative scatter plot of probe set values from three resting (x axis) and IL-15-activated (y axis) NK cell pairs, with Gzma, Gzmb, and Prf1
probe set values designated with arrows.
(C) Microarray signal intensity (mean ± SD) from three independent resting and IL-15-activated (24 hr) NK cell pairs for Prf1 and murine Gzm probe
sets on the Affymetrix 430v2.0 microarray. Also shown is the signal intensity of resting, unmanipulated WT spleen cells (n = 2 spleens, with arrays for
both performed in duplicate) for comparison. Values in italics indicate that these signals were Affymetrix ‘‘absent’’ calls (no specific detectable signal
present) on the microarrays.
(D) Quantitative real-time RT-PCR comparing resting and 24 hr IL-15-activated NK cell expression of Gzma, Gzmb, and Prf1 mRNAs. The mean ± SD
expression from at least four independent experiments is shown as fold-change of IL-15-activated (24 hr) compared to resting NK cells, utilizing the
comparative Ct method, with b-actin used as the control. *p < 0.05.IL-15-Activated NK Cells Require Gzmb and Prf1
for Potent Cytotoxicity In Vitro
We next examined whether Gzma, Gzmb, or Prf1 were
required for NK cell cytotoxicity in vitro (Figures 5E and
5F). Splenocytes from WT mice, Prf1/ mice, andGzmb/ mice (all in the B6 background) were used at
rest or after 48 hr in IL-15 as effectors in FloKAs against
RMAS tumor targets (Figure 5E). In this report, ‘‘Gzmb/’’
refers to mice with a retained Pgk-Neo cassette in the
Gzmb gene. These mice are deficient for Gzmb and alsoImmunity 26, 798–811, June 2007 ª2007 Elsevier Inc. 803
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Perforin and Granzyme A/B in Murine NK CellsFigure 5. Resting Murine Splenocytes Are Minimally Cytotoxic, and IL-15-Activated Splenocytes Require Gzmb and Prf1 to
Efficiently Kill Tumor Targets In Vitro
(A) Resting murine splenocytes exhibit minimal cytotoxicity against the NK-sensitive RMAS and YAC1 tumor cell lines that is increased by IL-15
activation. FloKAs (4 hr) were performed with resting or activated (48 hr IL-15) B6 splenocytes as effectors and the indicated tumor cell line as targets,
at E:T ratios of 5:1, 10:1, and 20:1. The NK-insensitive EL4 cell line is included as a negative control. For (A), (B), (C), (E), and (F), FloKA results shown
are the percent target cells that are 7-AAD positive (mean ± SD of replicate wells) from one experiment. The data (mean ± SD) shown are represen-
tative of at least three independent experiments.
(B) Multiple strains of mice exhibit minimal resting NK cell cytotoxicity, which is increased by IL-15 activation. Splenocytes from the indicated mouse
strains isolated fresh (resting) or after 48 hr of IL-15 activation were used as effector cells in a 4 hr FloKA against RMAS targets at the indicated E:T
ratios. Results (mean ± SD) shown are representative of three independent experiments.
(C and D) FloKA andCr51-release assays yield similar results, showing a time-dependent increase in NK cell cytotoxicity after IL-15 stimulation.WTB6
splenocytes were isolated and used fresh (0 hr) or at 12 hr, 24 hr, or 48 hr of IL-15 stimulation as effector cells in both FloKA (C) and Cr51-release (D)
assays against identical RMAS targets. Results (mean ± SD) shown are representative of two independent experiments.
(E) Splenocytes fromWT,Gzmb/, and Prf1/ (B6) were used as effector cells in a 4 hr FloKA at rest or after 48 hr of IL-15 stimulation against RMAS
tumor targets at 5:1, 10:1, and 20:1 E:T ratios. Results (mean ± SD) shown are from one experiment representative of at least three independent
experiments.
(F) Splenocytes fromWT,Gzma/,Gzmb/,Gzma/Gzmb/, and Prf1/ (129/SvJ) were used as effector cells in a 4 hr FloKA after 48 hr of IL-15
stimulation against RMAS tumor targets. Results (mean ± SD) are representative of at least three independent experiments. For all experiments, spon-
taneous target cell death (FloKAs, percent targets positive for 7-AAD in target-only wells; Cr51-release, CPM in target-only wells) was routinely <10%
and subtracted to provide specific cytotoxicity data. Summary and comparative statistics are detailed in the Results section.804 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.
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Perforin and Granzyme A/B in Murine NK Cellsdisplay reduced Gzmc and Gzmf expression in LAK cells
and are therefore often referred to as Gzmb cluster-
deficient mice (Pham et al., 1996; Revell et al., 2005). As
previously noted (Figures 5A–5D), resting splenocytes
from all genotypes exhibited minimal cytotoxicity. IL-15-
activated Gzmb/ splenocytes (20:1 E:T, 21.7% ± 5.8%
7-AAD+, n = 7) had a significant defect in their cytotoxic
activity compared with WT NK cells (20:1 E:T, 54.2% ±
13.2% 7-AAD+, n = 7, p < 0.001). Similarly, IL-15-acti-
vated Prf1/ splenocytes (20:1 E:T, 10.9% ± 5.2% 7-
AAD+, n = 6) also had a severe cytotoxic defect compared
with WT splenocytes (20:1 E:T, 55.8% ± 8.8% 7-AAD+,
n = 6, p < 0.001). We repeated similar experiments with
IL-15-activated splenocytes by using mice derived in the
129/SvJ background, so that we could test strain-
matched Gzma/ and Gzma/Gzmb/ mice (Fig-
ure 5F). Results with WT, Gzmb/, and Prf1/ 129/SvJ
mice were similar to those observed with B6mice carrying
the same mutations. Splenocytes from Gzma/ mice
(20:1 E:T, 51.2%± 5.9% 7-AAD+, n = 6) had no detectable
defect in killing (20:1 E:T, 54.5% ± 13.8% 7-AAD+, n = 6).
Splenocytes from Gzma/Gzmb/ mice (20:1 E:T,
14.2% ± 3.1% 7-AAD+, n = 5) demonstrated significantly
less killing than those from Gzmb/ mice (20:1 E:T,
19.4% ± 3.1% 7-AAD+, n = 5, p < 0.01). Splenocytes
from Prf1/ mice consistently displayed the lowest
cytotoxic activity of all genotypes analyzed (20:1 E:T,
5.4% ± 3.3% 7-AAD+, n = 4; p < 0.01 compared to
Gzma/Gzmb/). These data show that activated
murine NK cells require Gzmb and Prf1 to acquire potent
cytotoxic potential against tumor targets in vitro.
Poly I:C Induces NK Cell Expression of Gzmb
and Prf1 Protein In Vivo
Mice were injected i.p. with poly I:C or PBS, and splenic
NK cells were analyzed after 24 hr for Gzma, Gzmb, and
Prf1 expression by flow cytometry and also were tested
for cytotoxic potential (Figure 6). The spleens of poly I:C-
injected mice had a markedly higher percentage of NK
cells positive for Gzmb and Prf1 than control mice (Figures
6A and 6B). As expected (Shresta et al., 1995), the spleno-
cytes from poly I:C-injected Gzmb/ and Prf1/ mice
displayed reduced killing (Figure 6C).
NK Cells Express Gzmb and Prf1 Protein In Vivo
after MCMV Infection
To further investigate patterns of Gzma, Gzmb, and Prf1
expression in NK cells activated in vivo, we analyzed the
well-characterized MCMV mouse model during the NK
cell-dependent phase of viral clearance. WT B6 mice
were infected with sublethal doses of Smith strain
MCMV and then analyzed on days 1, 2, 4, 6, and 8 after
MCMV infection for Gzma, Gzmb, and Prf1 expression in
NK cells (Figures 7A and 7B). The percentages of NK cells
expressing Gzmb and Prf1 increased concurrently,
peaked at day 2–4 after infection, and returned to baseline
by day 8. In contrast, the percentage of NK cells express-
ing Gzma was essentially constant throughout the
infection. Interestingly, both Ly49H+ and Ly49H NK cellsacquired Gzmb and Prf1 during MCMV infection,
suggesting that this upregulation was not specific for NK
cells stimulated by Ly49H-m157 interactions (data not
Figure 6. In Vivo Treatment with Poly I:C Induces NK Cell
Gzmb and Prf1 Protein and Cytotoxicity
(A and B) Mice were injected i.p. with 200 mg poly I:C or PBS (vehicle
control), and after 24 hr, splenic NK1.1+CD3 NK cell expression of
intracellular Gzma, Gzmb, and Prf1 was analyzed by flow cytometry.
Flow-cytometry data representative of at least three independent
experiments are shown (A), with a significant increase in the percent
NK cells positive (mean ± SD) for Gzmb and Prf1 after poly I:C injection
(B). *p < 0.001.
(C) Splenocytes from poly I:C- or PBS-injected mice were used
as effectors in a FloKA against RMAS target cells at a 100:1 E:T ratio.
Results (mean ± SD) are representative of two independent
experiments.Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc. 805
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Perforin and Granzyme A/B in Murine NK CellsFigure 7. MCMV Infection Induces NK Cell Gzmb and Prf1 Protein, which Are Required for Host Defense and Survival
(A and B) NK cell expression of Gzma, Gzmb, and Prf1 protein by flow cytometry after MCMV infection. Mice were infected with 53 104 pfu MCMV/
mouse, and splenocytes were harvested from naive mice or at days 1, 2, 4, 6, and 8 after infection (n = 3 mice/time point) and analyzed for NK cell
expression of intracellular Gzma, Gzmb, and Prf1. Representative plots from individual mice are shown (A), and the percent NK cells positive for
Gzma, Gzmb, and Prf1 are summarized for one experiment (B), with each dot indicative of one mouse and the mean shown as a horizontal bar
with SD. These data are representative of 2–5 independent experiments.
(C) MCMV titers in wild-type (WT), Gzmb/, and Prf1/ mice (B6 background). Mice were infected with 1 3 105 pfu MCMV/mouse. Spleens
were harvested on day 3 after infection and analyzed by plaque assay for MCMV titers. Combined results from two independent experiments
demonstrate that Gzmb/ (n = 9, p < 0.001) and Prf1/ (n = 5, p < 0.01) had significantly higher MCMV titers in the spleen compared to WT
mice (n = 9).
(D) Survival after MCMV infection in WT,Gzmb/, and Prf1/mice. Groups of WT,Gzmb/, and Prf1/ (B6 background) mice were infected with
MCMV (day 0) and followed for survival. Kaplan-Meier analysis is shown, with significantly inferior survival compared to WT in both Gzmb/ and
Prf1/ mice (p < 0.001) at two different MCMV doses: left, 1 3 105 pfu/mouse (females); right, 2.5 3 105 pfu/mouse (males). All p values shown
on the survival curves indicate significance compared to WT mice. There is also a significant difference between the Gzmb/ and Prf1/ curves
(p = 0.003) at the 1 3 105 pfu dose in females (left).shown). Similarly, IL-15-activated splenocytes showed
similar induction of Gzmb and Prf1 protein at early time
points in both Ly49H+ and Ly49H subsets (Figure S6).
Therefore, murine NK cells acquire Gzmb and Prf1 protein
during the innate immune response to MCMV in vivo.806 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.Gzmb/ and Prf1/ Mice Exhibit Higher Mortality
than WT Mice after MCMV Infection
Although previous reports have identified defects in host-
defense against MCMV infection in Prf1/ mice (Loh
et al., 2005; Tay and Welsh, 1997), the role of Gzms for
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yet been well defined. Spleens from MCMV-infected WT,
Gzmb/, and Prf1/ B6 mice were assayed for MCMV
titers at day 3 after infection (Figure 7C). Both Gzmb/
(p < 0.001) and Prf1/ (p < 0.01) mice had significantly
elevated viral titers in the spleen at day 3 (compared
withWTmice), demonstrating that control of MCMV infec-
tion was compromised in these mice.
We next monitored the survival of age- and sex-
matched WT B6, Gzmb/, and Prf1/ mice infected
with 1 3 105 or 2.5 3 105 pfu/mouse Smith strain MCMV
(Figure 7D). Kaplan-Meier analysis demonstrated a signifi-
cant increase in mortality in both Gzmb/ and Prf1/
mice (Figure 7D, p < 0.001), with the observed deaths
occurring between days 5 and 8 after infection. At the
2.53 105 pfu dose of MCMV, Gzmb deficiency was nearly
as detrimental as the absence of Prf1; however, at the
lower dose of 13 105 pfu, greater mortality was observed
inPrf1/mice (p = 0.003). Additional experiments at vary-
ing doses of MCMV demonstrated that the LD50 for
Gzmb/ mice was 25% that of WT mice, whereas the
LD50 of Prf1
/ mice was <10% that of WT B6 mice
(data not shown). Thus, Gzmb/ and Prf1/ mice clear
MCMV inefficiently and exhibit increased mortality after
MCMV infection.
DISCUSSION
In this report, we demonstrate that murine NK cells de-
rived from common laboratory strains of mice housed in
SPF conditions contain little or no Gzmb and Prf1 protein,
which provides a mechanism to explain why they are min-
imally cytotoxic at rest. NK cells isolated from the blood,
spleen, liver, and bone marrow of mice all had similar,
low amounts of Gzmb and Prf1, but they contained abun-
dant Gzma protein. Although several cytokines (IL-12, IL-
18, IFN-a) were able to induce fractions of NK cells to
translate Gzmb and Prf1 protein in bulk splenocyte cul-
tures, only IL-2 and IL-15 stimulated substantial amounts
in both bulk splenocytes and flow-sorted NK cells, with IL-
15 being the most efficient. The striking increase in Gzmb
and Prf1 protein abundance was accompanied by only
small changes in mRNA levels, suggesting that activation
is due to the release of a block in mRNA translation. The
requirement for Gzmb and Prf1 for potent NK cytotoxicity
in vitro was confirmed with Gzmb/ and Prf1/ mice.
The minimal residual killing detected in Prf1/ mice sug-
gests that other contact-dependent killing pathways (e.g.,
FasL, TRAIL) are minimally utilized in this experimental
system, consistent with the small amounts of these pro-
teins detected on the surface of IL-15-activated NK cells
at 24–48 hr (data not shown).
Most studies examiningmurine NK cell cytotoxicity over
the past 15 years have utilized either poly I:C-injected
mice or IL-2-activated adherent NK cells (i.e., LAK cells)
as ‘‘surrogates’’ for NK cells. Our data strongly suggest
that the minimal in vitro cytotoxicity exhibited by resting
mouse NK cells is due to the low amounts of Gzmb and
Prf1 in these cells, and that poly I:C or long-term culturein high-dose IL-2 was necessary to induce expression of
these proteins in these past studies, allowing the cells to
become cytotoxic. In contrast, a few reports have sug-
gested that freshly purified, resting murine NK cells exhibit
substantial cytotoxicity against tumor target cells in vitro
(Kim et al., 2002; Vosshenrich et al., 2005). Although the
reason for the discrepancy is not immediately clear, it is
possible that undetected infections of the Rag-deficient
mice used in these studies may have caused NK cell
activation or that technical approaches to cytotoxicity
measurements are now more sensitive and reproducible.
Several groups have reported rapid (6–24 hr) clearance
of intravenously injected tumor cells and have therefore
suggested that resting NK cells may be fully ‘‘armed.’’
However, our studies have clearly shown that IL-15 can
begin to induceGzmbandPrf1 production fromapreexist-
ing pool of mRNA within 6 hr of treatment in vitro, and
therefore these data are not inconsistent with our observa-
tions. Regardless, the complex variables that determine
the clearance rates of many tumor cell lines in vivo are
not yet well understood (e.g., tumor cell trafficking, im-
mune activation, effector compartments, etc.), and all
could play roles in clearance kinetics. Finally, in vivo tumor
clearance may not be an accurate measure of Prf1-
dependent NK cytotoxicity (Grundy et al., 2006).
We have demonstrated that resting murine NK cells are
‘‘pre-armed’’ with high amounts of Gzmb and Prf1 mRNA,
which NK cells can rapidly translate into protein upon
activation in vitro and in vivo. The use of such amechanism
by murine NK cells to control Gzmb and Prf1 would allow
for the rapid production of effector proteins without the
need for new gene transcription. Interestingly, resting mu-
rine NK cells have previously been shown to constitutively
express IFN-g mRNA—but not protein—which is rapidly
translated upon activation (Stetson et al., 2003). Previous
reports have also demonstrated that murine memory
CTLs express abundant Gzmb mRNA, but do not contain
detectable amounts of Gzmb protein (Kaech et al., 2002).
Similarly, we have shown a more rapid increase in Gzmb
protein production after the in vitro activation of human
memory CD4+ T cells compared to naive CD4+ T cells
(Grossman et al., 2004b). Thus, the pre-arming of cyto-
toxic lymphocytes with effector mRNAs may be a general
mechanism that many kinds of cytotoxic lymphocytes use
to allow these cells to rapidly respond to dangerous
stimuli.
The presence of abundant Gzma protein in resting
murine NK cells contrasts sharply with that of Prf1 and
Gzmb. Gzma is one of the most highly expressed genes
in both resting and activated NK cells, suggesting a key
role in murine NK cell physiology. Because Gzma mRNA
and protein expression remain relatively constant in
resting and activated NK cells, this gene exhibits a funda-
mentally different pattern of regulation than does Gzmb
and Prf1. Despite the abundance of Gzma, Gzma-
deficient NK cells kill tumor targets normally in vitro,
consistent with previous reports that used other cytotoxic
effectors (Ebnet et al., 1995a; Mullbacher et al., 1996;
Pereira et al., 2000; Shresta et al., 1999). NK cells fromImmunity 26, 798–811, June 2007 ª2007 Elsevier Inc. 807
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derived from Gzmb/ mice, suggesting that Gzma may
serve as a ‘‘fail-safe’’ mechanism for killing target cells
that contain inhibitors of Gzmb (Shresta et al., 1999;
Russell and Ley, 2002).
While several previous reports have examined late, non-
NK-dependent MCMV responses in Prf1/, Gzma/,
and/or Gzmb/ mice (Cheeran et al., 2005; Dix et al.,
2003; Riera et al., 2000), the role of these proteins for
innate, NK-dependent responses (Biron et al., 1999;
Bukowski et al., 1983) had not previously been fully exam-
ined. Specific NK control of MCMV in B6mice results from
NK cell recognition of the virally encoded m157 protein
(Arase et al., 2002; Smith et al., 2002) on the surface of
infected cells by the activating NK receptor Ly49H (Brown
et al., 2001; Daniels et al., 2001; Lee et al., 2001). The
importance of Prf1 for early NK-dependent responses
was demonstrated by elevated viral titers and decreased
survival during MCMV infection in Prf1/ mice (Loh
et al., 2005; Tay and Welsh, 1997). Here, we show that
MCMV infection induces NK cell Prf1 and Gzmb protein
production that peaks 2–4 days after infection and disap-
pears by day 8. MCMV induces a number of candidate
cytokines, which are produced by plasmacytoid dendritic
cells and other innate immune cell types (Andoniou
et al., 2005; Andrews et al., 2003; Dalod et al., 2003;
Krug et al., 2004; Nguyen et al., 2002). Our in vitro studies
suggest that IL-15 is a leading candidate for the observed
induction; however, it is likely that multiple pathways
synergize to activate NK Gzmb and Prf1 protein in vivo.
To begin to address whether NK receptors play a role in
this synergistic activation pathway, we evaluated the abil-
ity of activating NK receptor ligation (plate-bound NK1.1
or NKG2D or coculture with Baf/3 cells that express
m157 [Ho et al., 2002; Kim et al., 2005]) to induce Gzmb
or Prf1 protein in splenic NK cells after 12–48 hr. Ligation
of individual NK receptors (NK1.1, NKG2D, or Ly49H) in
these settings did not result in increased NK cell Gzmb
or Prf1 protein translation, according to experimental
conditions that result in IFN-g production (data not
shown). Thus, cytokines (and possibly other signals) may
well represent the arming pathway that stimulates the
translation of Gzmb and Prf1, which provides the potential
for potent cytotoxicity. NK-receptor ligation probably
represents the ‘‘trigger’’ that leads to directed granule
release at the NK-target-cell synapse.
Experiments examining viral titers and survival demon-
strate an important role for Gzmb cluster enzymes in
MCMV clearance and confirm the essential role of Prf1.
We were unable to evaluate the impact of Gzma/ NK
cells during MCMV infection because the mutation cre-
ated in our laboratory was derived in 129/SvJ mice, which
lack Ly49H and specific NK-mediated MCMV resistance.
Definitive evaluation of the contribution of Gzma to innate
host defense against MCMV awaits the backcross of our
Gzma/mice to the B6 background, which is in progress.
A recent study that used a lower MCMV dose (13 104 pfu)
reported no significant differences in viral titers in the
spleens of Gzmb/ and Gzma/ mice compared with808 Immunity 26, 798–811, June 2007 ª2007 Elsevier Inc.WT mice, although higher titers were observed in
Gzma/Gzmb/ and Prf1/ mice (van Dommelen
et al., 2006). In addition, no mortality was observed in
Gzmb/ or Gzma/Gzmb/ mice. However, because
LD50 values for the Gzm-deficient mice were not deter-
mined, it is possible that the apparent discrepancy
between the studies reflects differences in the MCMV
doses used. Regardless, both studies suggest that
Gzmamay play a role in NK-dependent MCMV responses
in vivo.
Our findings in murine NK cells contrast sharply with
observations made with the majority of resting human
NK cells from the peripheral blood of healthy individuals,
which express Gzma, Gzmb, and Prf1 protein and are
cytotoxic (Bratke et al., 2005; Cooper et al., 2001; Gross-
man et al., 2004b). One potential explanation for the ob-
served differences may derive from the chronic exposure
of humans to infectious pathogens; SPF laboratory mice
have few exposures to pathogens that activate the innate
immune system. Alternatively, there may be fundamental
differences between murine and human NK cell cytotoxic
granule gene regulation, with different mechanisms of pre-
arming at the levels of mRNA versus protein. However, it is
notable that the CD56bright human NK cell subset is mini-
mally cytotoxic at rest, expresses little Gzmb or Prf1 but
considerable Gzma protein, and becomes potently cyto-
toxic only after cytokine activation (Bratke et al., 2005;
Cooper et al., 2001); this mimics our findings with mouse
NK cells. A similar profile of Gzm and Prf1 protein expres-
sion has been noted in CD8+ T cells in patients who fail to
clear chronic viral infections (Andersson et al., 1999; Chen
et al., 2001); a posttranscriptional mechanism could also
help to explain these findings. The differences between
mouse and human NK cell biology are important, because
mice serve as an essential model system to understand
innate immune responses to infection and malignancy.
The identification of differences between mouse and
humanNK cell Prf1 andGzm expression patterns highlight
the importance of assessing both species to obtain a
complete understanding of NK cell biology.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
WTC57Bl/6, 129/SvJ, BALB/c, CBA, A/J, and Rag1/ (B6) mice were
obtained from the Jackson Laboratory. The following mouse strains
were previously described: Gzmb/ mice (Heusel et al., 1994), which
were backcrossed to B6J for 12+ generations (Revell et al., 2005); and
Gzma/ (Shresta et al., 1999), Gzmb/ (Revell et al., 2005), and
Gzma/Gzmb/ mice, which were all derived in the 129/SvJ back-
ground (Revell et al., 2005). Prf1/ mice (B6) were obtained from
Jackson Laboratory (Kagi et al., 1994) and were backcrossed to
129/SvJ with a speed congenic approach for six generations; founders
used to generate the colony had >98% 129/SvJ markers. EL4 (ATCC),
YAC1, and RMAS (a kind gift of W. Yokoyama) cell lines were grown in
K10 media (RPMI 1640, 10% FCS, 10 mM HEPES, 1% NEAA, 1% so-
diumpyruvate, 1%L-glutamine, 13penicillin/streptomycin, 0.57mMb-
ME). The murine 36.2 NK line was maintained in K10 + 1000 U/mL
recombinant (r) human IL-2 (MacIvor et al., 1999). All mice were main-
tained in SPF housing, and all experiments were conducted in accor-
dance with institutional animal care and use guidelines.
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mAbs used were anti-mouse NK1.1 (PK136), CD3 (145-2C11), CD49b
(DX5), CD16/32 (2.4G2) (BD Biosciences), Prf1 (eBioscience, OMAK-
D), and Gzmb (Caltag, GB12). The anti-mouse Gzma mAb was pro-
duced in our laboratory and is available from Santa Cruz (3G8.5),
with Gzma specificity shown in Figure S1. For immunoblots, rat anti-
Prf1 (P1-8, Kamiya, 1:5000), polyclonal rabbit anti-Gzmb (526B,
1:1000) (Shresta et al., 1999), and goat anti-actin (C-11, Santa Cruz,
1:1000) were used and developed with HRP secondary Abs (Amer-
sham, 1:5000). Anti-NKG2D mAbs C7 and A10 were kind gifts of
W. Yokoyama. Cytokines were obtained from R&D Systems (rmIL-15,
rmIL-12, rmIL-18, and rmIFN-a) or Chiron (rhIL-2). All cytokines were
endotoxin free and stored at 80C after reconstitution in PBS +
0.1% BSA. Poly I:C was obtained from Sigma.
Cell Isolation and Stimulation
Spleens were harvested and single-cell suspensions were generated
by pressing through sterile 70 mM nylon mesh. RBCs were lysed and
cells washed in complete K10 medium. For in vitro cytokine stimula-
tion, splenocytes were plated at 10 3 106/mL in 24-well plates in
100 ng/mL IL-15 (or at the indicated concentration), 1000 U/mL IL-2,
100 ng/mL IL-12, or 100 ng/mL IL-18. Cells were harvested by pipet-
ting with cold PBS after 48 hr (or as indicated), and analyzed by flow
cytometry or used as effector cells in FloKAs. For cell sorting, spleno-
cytes were surface stained with anti-NK1.1 or DX5 and anti-CD3
mAbs, and NK1.1+CD3 or DX5+CD3 cells were isolated on a MoFlo
cell sorter (routinelyR99% pure).
Flow-Based Killing and Cr51 Release Assays
Flow-based killing assays (FloKAs) (4 hr) were performed as described
(Grossman et al., 2004a, 2004b; Revell et al., 2005), utilizing resting or
activated splenocytes or purified NK cells as effectors, and the NK-
sensitive RMAS, YAC1, or NK-resistant EL4 tumor cell lines as targets
at E:T ratios of 20:1, 10:1, and 5:1 (or as indicated) in 2–3 replicate
wells. Controls included target-only wells for background (spontane-
ous) cell death and effector-only wells to ensure that target cells only
were in the CFSE gate. Results are shown as mean percent 7-AAD+
target cells ± SD, with background death subtracted. Cr51-release as-
says were performed as previously described (Shresta et al., 1995).
Intracellular Staining and Flow Cytometry
Splenocytes or tissue mononuclear cells were stained for surface
markers and intracellular Gzma, Gzmb, or Prf1 as described (Gross-
man et al., 2004a, 2004b; Revell et al., 2005) with directly conjugated
Gzma (1:400 dilution), Gzmb (1:400 dilution), or Prf1 (2.5 mg/mL)
mAbs. Sample data were acquired on a Cytek-modified FACScan
(BD) or FC500 (Coulter) flow cytometer and analyzed with CXP (Coul-
ter) or FloJo (TreeStar) software. Isotype controls were used to set
quadrant gates.
Immunoblots
Protein lysates were generated from resting or IL-15-activated bulk
spleen or flow-sorted NK cells. Reducing SDS-PAGE, transfer to
PVDF membranes, and immunoblots for Prf1, Gzmb, or actin were
performed as described (Revell et al., 2005; Shresta et al., 1999).
RNA Isolation and Microarrays
RNA isolation andmicroarray processing and analysis were performed
as described (Yuan et al., 2007), with flow-sorted NK cell samples or
spleens at rest or after 24 hr of IL-15 activation, with linear amplifica-
tion, on Affymetrix 430v2.0 expression arrays. Analysis was performed
with DecisionSite for Functional Genomics software (Spotfire, Somer-
ville, MA) or Microsoft Excel (Microsoft, Redmond, WA). Scatter plots
were generated after removing probesets that were Affymetrix
‘‘absent’’ calls on all microarrays. Microarray data are available at
the Gene Expression Omnibus (GEO) microarray database (http://
www.ncbi.nlm.nih.gov/geo/), accession number GSE7764.Quantitative Real-Time RT-PCR
Total RNA was isolated from paired (resting and 24 hr IL-15-activated)
flow-sorted NK cell samples (2.5 3 105) with the RNeasy Micro Kit
(Qiagen). qRT-PCR was performed as described for Gzma and
Gzmb (Revell et al., 2005), and for Prf1 the following primers were
used: forward, 50-GATGTGAACCCTAGGCCAGA-30; reverse, 50-AAA
GAGGTGGCCATTTTGTG-30. Comparisons were made by the com-
parative Ct method, with b-actin serving as the comparator, because
this mRNA did not significantly change between resting and IL-15-
activated NK cells (Figure 4). Data are presented as fold-change
relative to resting NK cell samples, which are set to a value of 1.
MCMV Infection, Plaque Assays, and Poly I:C Injections
Smith strainMCMVwas kindly provided byW. Yokoyama (Washington
University, St. Louis, MO). A salivary gland stock of MCMV was pre-
pared from BALB/c mice that had been i.p. injected with 1 3 106 pfu
tissue-culture-propagated MCMV, and the titer of the stock was deter-
mined via standard plaque assay (Brown et al., 2001) with NIH 3T12
fibroblasts (ATCC; Manassas, VA). For experiments, mice were
injected i.p. with 5 3 104 to 2.5 3 105 pfu/mouse salivary gland Smith
MCMV stock. For survival curves, mice were observed daily after
infection for 21 days, and moribund mice were euthanized per institu-
tional guidelines. For viral titer plaque assays, spleens from day 3 after
infection were frozen in D10 media and homogenized by bead beating
(BioSpec), and titers were read in triplicate as described (Heise and
Virgin, 1995) and are presented as log pfu/spleen. Poly I:C (200 mg)
or vehicle (PBS) was injected i.p., and 24 hr later, spleens were
harvested to assess Gzm/Prf1 expression and cytotoxicity.
Light Microscopy
Light microscopy on flow-sorted murine NK cells stained with Wright/
Giemsa were performed as described (Grossman et al., 2004a).
Statistics
Two-tailed t tests were used to determine significant differences
(p < 0.05); Kaplan-Meier analysis was performed with Prism software
(Graph Pad, San Diego, CA).
Supplemental Data
Six figures are available at http://www.immunity.com/cgi/content/full/
26/6/798/DC1/.
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Note Added in Proof
After this paper was submitted, Lucas et al. have shown that IL-15
presented ‘‘in trans’’ on the surface of dendritic cells during the innate
immune response to infection arms resting murine NK cells by increas-
ing Gzmb expression and cytotoxicity against tumor targets in vitro
(Lucas, M., Schachterle, W., Oberle, K., Aichele, P., and Diefenbach,
A. (2007). Dendritic cells prime natural killer cells by trans-presenting
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